Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.53 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7924905 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL2124440 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL8806720 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL5379043 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL8526392 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL4359525 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL9008818 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL5379107 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL5395207 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL1685004 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4180424-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-02-23 | — | — | US | disclosed |
| US-11192861-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3828173-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-02-18 | — | — | US | disclosed |
| EP-3113772-B1 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| CN-1478078-A | Nitrogen-containing aromatic ring derivatives | ������������ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| US-5532365-A | NITROGUANIDINE COMPOUNDS AS INSECTICIDES | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-02 | — | — | US | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| US-5444056-A | Hypotensive agnets, calcium channel blockers | SANOFI (FR) | 1995-08-22 | — | — | US | disclosed |
| EP-0260605-B1 | Dihydropyridine-5-phosphonic acid cyclic ester | NISSAN CHEMICAL IND LTD (JP) | 1994-03-23 | — | — | EP | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| US-5081114-A | STEROIDS | ROUSSEL UCLAF (FR) | 1992-01-14 | — | — | US | disclosed |
| US-5019585-A | Tricyclic aromatase inhibitors | AKZO N.V. (NL) | 1991-05-28 | — | — | US | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| EP-0253498-A2 | Tertiary amine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ESR1 3818/4885LMNA 1195/4885SLC15A2 2523/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ESR1 4079/4885LMNA 1126/4885SLC15A2 2636/4885 |
| US-11192861-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ESR1 3818/4885LMNA 1195/4885SLC15A2 2523/4885 |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ESR1 3818/4885LMNA 1195/4885SLC15A2 2523/4885 |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ESR1 3740/4885LMNA 998/4885SLC15A2 2326/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ESR1 4013/4885LMNA 824/4885SLC15A2 2392/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ESR1 3740/4885LMNA 998/4885SLC15A2 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.